Printed From BioPortfolio.com
Breakthrough study could revolutionise MS treatment
05:03 EDT 13 Oct 2017 | Pharmafile
The results of a study from the University of California, San Francisco will be welcomed with a certain excitement from all quarters, given that it seems to show the repair of myelin damaged by multiple sclerosis (MS) and, to add to the news, is achieved through the use of a generic allergy medication.
The Phase 2 clinical trial showed that an antihistamine was able to restore nervous system function in patients with chronic MS. The treatment would be the first that had the potential to reverse damage inflicted by the demyelinating disease.
Original Article: Breakthrough study could revolutionise MS treatment
